Ipca Laboratories Ltd

₹ 1,517 0.61%

14 Jan

🔗 Website | BSE: 524494 | NSE: IPCALAB

Market Cap38,487

Current Price1,517

High / Low1,599

Stock P/E39.7

Book Value292

Dividend Yield0.26

ROCE17.6

ROE12.6

ABOUT

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)

Stock Analysis

### Description Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals. ### Key Growth Triggers Currently no data available for Key Growth Triggers. ### Order Book Currently no data available for Order Book. ### Key Red Flags Currently no data available for Key Red Flags. ### Key Dates To Watch Agreement for sale of Bayshore Pharmaceuticals expected around January 20, 2026. Sale completion expected within 30 days thereafter.

Peer Comparison

S.No.	Name	Current Price (Rs.)	Price to Earning	Market Capitalization (Rs.Cr.)	Dividend yield (%)	Net Profit latest quarter (Rs.Cr.)	YOY Quarterly profit growth (%)	Sales latest quarter (Rs.Cr.)	YOY Quarterly sales growth (%)	Return on capital employed (%)	Sales (Rs.Cr.)	OPM (%)	Profit after tax (Rs.Cr.)	Profit after tax latest quarter (Rs.Cr.)	Price to book value	Return on assets (%)	Debt to equity
1.	Sun Pharma.Inds.	1700.70	35.35	408054.90	0.94	3124.95	2.56	14478.31	8.93	20.21	54964.01	30.12	11543.96	3117.95	5.24	12.97	0.07
2.	Divi's Lab.	6355.50	67.89	168718.56	0.47	689.00	35.10	2715.00	16.12	20.44	10029.00	32.37	2485.00	689.00	10.95	13.53	0.01
3.	Torrent Pharma.	4003.70	62.54	135503.40	0.80	591.00	32.49	3302.00	14.30	27.05	12248.00	32.60	2166.53	600.17	16.04	13.26	0.33
4.	Cipla	1434.50	21.30	115874.78	0.91	1353.37	3.73	7589.44	7.64	22.72	28349.57	25.40	5441.14	1351.17	3.52	14.72	0.01
5.	Lupin	2195.90	23.19	100308.45	0.55	1484.83	73.34	7047.51	24.23	21.30	24750.69	27.25	4324.63	1477.92	5.11	12.41	0.32
6.	Dr Reddy's Labs	1186.50	17.16	99028.89	0.67	1336.80	7.28	8828.30	9.83	22.69	34310.00	24.64	5772.20	1347.10	2.75	12.95	0.16
7.	Mankind Pharma	2244.40	52.99	92649.97	0.04	520.18	-22.00	3697.16	20.77	15.98	13545.67	24.12	1748.55	511.51	6.06	8.89	0.55
8.	Ipca Labs.	1517.00	39.73	38486.93	0.26	304.74	24.83	1930.32	6.59	17.58	6978.34	23.52	968.63	304.74	5.20	9.41	0.11

Quarterly Results

Figures in Cr.

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	1,495	1,440	1,402	1,486	1,663	1,507	1,511	1,566	1,811	1,663	1,638	1,747	1,930
YOY Sales Growth %	4.97%	8.4%	19%	0.54%	11.25%	4.63%	7.78%	5.35%	8.92%	10.34%	8.46%	11.56%	6.59%
Expenses	1,224	1,229	1,226	1,189	1,314	1,234	1,218	1,213	1,409	1,252	1,280	1,340	1,466
Material Cost %	33.75%	34.86%	38.54%	31.92%	32.17%	32.21%	32.02%	28.9%	29.59%	27.62%	27.19%	25.64%	26.45%
Employee Cost %	19.89%	20.67%	21.24%	22.37%	20.22%	22.19%	22.06%	23.07%	21.12%	21.56%	23.02%	23.46%	21.31%
Operating Profit	270	211	176	298	348	273	292	353	402	411	359	407	465
OPM %	18%	15%	13%	20%	21%	18%	19%	23%	22%	25%	22%	23%	24%
Other Income	36	24	33	43	-3	17	-79	15	17	17	-260	25	22
Exceptional items	0	0	0	0	-39.29	0.45	-94.32	0	0	0	-281.54	0	0
Other income normal	35.59	24.2	33.47	43.16	36.14	16.89	15.1	15.39	17	17.41	21.49	25.02	21.92
Interest	9	10	18	31	39	27	24	19	17	10	16	12	11
Depreciation	56	58	59	60	61	63	62	61	63	63	65	63	67
Profit before tax	240	166	132	250	245	200	127	288	339	356	17	357	408
Tax %	31%	31%	36%	33%	34%	32%	49%	29%	28%	25%	479%	27%	25%
Net Profit	166	115	85	167	162	137	65	204	244	268	-65	262	305
EPS in Rs	6.53	4.54	3.34	6.57	6.39	5.4	2.55	8.05	9.62	10.55	-2.56	10.33	12.01

Profit & Loss

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	3,235	3,088	2,804	3,102	3,193	3,606	4,338	5,114	5,405	5,775	6,124	6,678	6,978
Sales Growth %	—	—	—	—	—	—	—	—	—	—	—	—	—
Expenses	2,498	2,556	2,526	2,666	2,748	2,909	3,419	3,596	4,164	4,858	4,909	5,153	5,337
Material Cost %	—	—	—	—	—	—	—	—	—	—	—	—	—
Raw material cost	—	—	—	—	—	—	—	—	—	—	—	—	—
Change in inventory	—	—	—	—	—	—	—	—	—	—	—	—	—
Manufacturing Cost %	—	—	—	—	—	—	—	—	—	—	—	—	—
Employee Cost %	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Cost %	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating Profit	737	532	277	436	446	697	918	1,518	1,241	917	1,215	1,525	1,641
OPM %	23%	17%	10%	14%	14%	19%	21%	30%	23%	16%	20%	23%	24%
Other Income	21	32	26	19	39	54	64	61	53	108	-23	-210	-196
Exceptional items	—	—	—	—	—	—	—	—	—	—	—	—	—
Other income normal	—	—	—	—	—	—	—	—	—	—	—	—	—
Interest	28	29	31	26	27	21	19	11	10	46	123	63	50
Depreciation	101	177	161	171	174	172	179	188	210	229	246	252	258
Profit before tax	629	358	111	258	283	557	785	1,380	1,074	750	822	1,000	1,138
Tax %	24%	28%	17%	27%	18%	18%	17%	17%	20%	33%	35%	35%	—
Net Profit	477	256	93	188	233	455	652	1,141	860	506	530	651	769
Exceptional items AT	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit excl Excep	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit for PE	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit for EPS	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS in Rs	18.91	10.15	3.67	7.46	9.24	18	25.82	44.97	33.91	19.93	20.91	25.65	30.33
Dividend Payout %	13%	5%	0%	7%	5%	8%	10%	9%	12%	20%	19%	16%	—

Balance Sheet

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	25	25	25	25	25	25	25	25	25	25	25	25	25
Reserves	1,956	2,208	2,258	2,450	2,670	3,111	3,652	4,727	5,450	5,852	6,323	6,866	7,382
Borrowings	595	929	865	716	628	444	474	236	776	1,440	1,152	906	780
Long term Borrowings	292	501	484	352	234	134	78	9	395	652	542	482	357
Short term Borrowings	138	321	183	177	239	196	309	214	366	771	591	389	375
Lease Liabilities	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Borrowings	165	106	198	187	155	114	68	0	0	0	0	—	—
Other Liabilities	641	662	756	777	785	877	1,033	1,021	1,186	1,129	1,159	1,273	1,374
Trade Payables	337	303	415	388	415	464	538	526	492	451	423	482	502
Advance from Customers	9	22	0	0	0	0	0	0	27	27	15	—	—
Other liability items	295	337	341	389	370	413	495	495	668	651	721	792	872
Total Liabilities	3,217	3,824	3,905	3,968	4,108	4,458	5,185	6,010	7,438	8,447	8,659	9,071	9,562
Fixed Assets	1,306	1,753	1,977	1,946	1,855	1,740	1,841	1,869	2,153	2,479	2,524	2,543	2,695
Land	65.99	98.39	98.07	98.07	98.34	98.34	218.52	189.26	238.4	234.43	247.15	—	—
Building	360.89	486.74	476.12	508.58	513.45	517.19	538.81	549.11	666.86	750.82	778.27	—	—
Plant Machinery	1,140.9	1,457.32	1,232.72	1,311.46	1,365.98	1,403.7	1,520.7	1,704.65	1,989.39	2,376.57	2,582.22	—	—
Equipments	188.92	266.27	209.13	224.66	245.42	253.08	250.09	260.36	303.8	345.4	356.49	—	—
Furniture & fittings	—	—	—	—	—	—	—	—	—	—	—	—	—
Vehicles	23.25	25	15.23	15.97	16.38	16.28	19.1	19.88	22.33	28.45	32.72	—	—
Intangible Assets	22.06	50.94	34.02	39.23	39.23	39.23	46.73	42.42	26.63	26.63	26.63	39.53	43.08
Other fixed assets	16.77	25.6	27.43	31.23	30.56	34.21	41.61	78.27	57.54	59.6	69.23	—	—
Gross Block	1,851.29	2,465.9	2,137.32	2,276.99	2,358.72	2,412.97	2,688.79	2,899.27	3,364.68	3,889.09	4,165.82	—	—
Accumulated Depreciation	545.18	712.94	160.74	331.02	504.11	672.87	847.82	1,030.67	1,211.59	1,410.43	1,642.12	—	—
CWIP	165	267	129	95	73	66	84	182	297	123	175	484	546
Investments	29	82	97	212	216	322	649	868	1,339	1,057	2,654	2,693	2,850
Other Assets	1,717	1,722	1,702	1,716	1,964	2,329	2,611	3,092	3,650	4,789	3,306	3,351	3,471
Inventories	838	917	832	874	873	1,056	1,267	1,517	1,780	1,660	1,677	1,542	1,512
Trade receivables	449	354	441	502	594	632	839	774	824	926	1,027	1,155	1,344
Receivables under 6m	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables over 6m	—	—	—	—	—	—	—	—	—	—	—	—	—
Prow for Doubtful	—	—	—	—	—	—	—	—	—	—	—	—	—
Cash Equivalents	69	113	162	18	131	260	152	307	596	1,706	113	165	141
Loans & Advances	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Assets items	—	—	—	—	—	—	—	—	—	—	—	—	—
Total Assets	3,217	3,824	3,905	3,968	4,108	4,458	5,185	6,010	7,438	8,447	8,659	9,071	9,562

Cash Flows

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	515	455	696	271	324	496	561	1,096	832	762	831	1,374
Profit from operations	763	540	313	420	468	732	966	1,552	1,295	957	1,221	1,606
Receivables	-93	107	191	-55	-92	-36	-211	79	-39	-101	-102	-133
Inventory	-105	-79	85	-42	0	-182	-211	-250	-241	119	-17	133
Payables	0	0	0	36	26	50	71	72	-46	-41	-29	58
Loans Advances	0	-27	29	0	0	0	0	0	0	0	0	0
Other WC items	79	-12	108	-34	-21	39	93	-115	54	44	34	36
Working capital changes	-118	-10	412	-95	-87	-129	-258	-215	-271	21	-114	93
Direct taxes	-130	-74	-29	-54	-57	-108	-146	-242	-192	-215	-277	-325
Cash from Investing Activity	-362	-686	-214	-146	-119	-123	-499	-560	-812	-710	-1,355	-739
Fixed assets purchased	-371	-555	-242	-135	-72	-67	-273	-350	-452	-437	-360	-603
Fixed assets sold	1	1	2	2	1	2	13	3	4	36	4	5
Investments purchased	-1,903	-2,038	0	-2,100	-2,456	0	0	0	-25	0	0	-6
Investments sold	1,906	2,046	4	2,107	2,463	0	0	0	0	0	0	0
Interest received	13	20	9	4	0	15	42	22	29	49	73	14
Redeemp Cnce of Shares	—	—	—	—	—	—	—	—	—	—	—	—
Acquisition of companies	0	0	0	0	-59	0	0	0	0	0	0	0
Other investing items	-0	-138	9	-21	-7	-1	-209	-159	-100	-244	540	-76
Cash from Financing Activity	-138	255	-414	-156	-130	-223	-139	-307	426	506	-465	-428
Redemption of debentures	0	-55	-5	-5	-5	0	0	0	0	0	0	0
Proceeds from borrowings	67	488	152	68	61	0	107	0	606	681	124	168
Repayment of borrowings	-111	-110	-517	-196	-182	-195	-115	-229	-67	-28	-417	-436
Interest paid fin	-28	-31	-28	-23	-22	-17	-16	-7	-6	-40	-117	-52
Dividends paid	-66	-37	-15	-0	-15	-15	-122	-102	-101	-101	-51	-101
Financial liabilities	0	0	0	0	0	0	-4	-6	-6	-5	-5	-7
Other financing items	0	0	0	0	33	0	12	0	0	0	0	0
Net Cash Flow	14	25	68	-31	74	150	-76	229	446	559	-990	207

Ratios

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	51	42	57	59	68	64	71	55	56	59	61	63
Inventory Days	271	293	290	288	286	332	312	350	364	293	309	297
Days Payable	109	97	145	128	136	146	133	121	101	80	78	93
Cash Conversion Cycle	213	238	203	219	218	250	250	284	319	272	293	268
Working Capital Days	83	69	62	75	82	93	91	108	105	74	87	120
ROCE %	27%	13%	4%	9%	9%	17%	20%	30%	19%	11%	14%	18%

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	46.29%	46.29%	46.29%	46.29%	46.29%	46.3%	46.3%	46.3%	44.72%	44.72%	44.72%	44.72%	44.72%
Bhawna Godha	0	0	0	0	0	0	0	0	0	0	0	0	0
Chandurkar Investments Private Limited	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5
Kalpana Jain	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09
Kaygee Investments Private Limited	21.47	21.47	21.47	21.47	21.47	21.47	21.47	21.47	21.47	21.47	21.47	25.49	25.49
Kaygee Laboratories Private Limited	6.61	6.61	6.61	6.61	6.61	6.61	6.61	6.61	6.61	6.61	6.61	6.61	6.61
Makers Laboratories Limited	0	0	0	0	0	0	0	0	0	0	0	0	0
Mexin Medicaments Private Limited	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	—	—
Neetu Godha	0	0	0	0	0	0	0	0	0	0	0	0	0
Nirmal Jain	0	0	0	0	0	0	0	0	0	0	0	0	0
Paranthapa Investments and Traders Pvt_ Ltd_	0.01	—	—	—	—	—	—	—	—	—	—	—	—
Paschim Chemicals Pvt Ltd	4	4	4	4	4	4.01	4.01	4.01	4.01	4.01	4.01	—	—
Pranay Godha	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
Prashant Godha	0.62	0.62	0.62	0.62	0.62	0.62	0.62	0.62	0.62	0.62	0.62	0.62	0.62
Premchand Godha	2.29	2.29	2.29	2.29	2.29	2.29	2.29	2.29	2.29	2.29	2.29	2.29	2.29
Sameer M Chandurkar	0.79	0.79	0.79	0.79	0.79	0.79	0.79	0.79	0.79	0.79	0.79	0.79	0.79
Usha M Chandurkar	3.27	3.27	3.27	3.27	3.27	3.27	3.27	3.27	1.7	1.7	1.7	1.7	1.7
Usha Premchand Godha	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
Xbees Traders LLP (Formerly Paranthapa Investments___	—	0.01	0.01	—	—	—	—	—	—	—	—	—	—
Xbees Traders Llp	—	—	—	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
FIIs	10.46%	10.58%	10.05%	9.86%	10.27%	10.51%	10.85%	10.83%	11.06%	10.75%	10.67%	10.42%	10.62%
Abu Dhabi Investment Authority - Monsoon	—	—	—	—	1.03	1.12	1	—	—	—	—	—	—
Kotak Funds - India Midcap Fund	—	—	1.21	1.29	1.29	1.36	1.36	1.36	1.34	1.29	1.26	1.26	1.24
DIIs	33.71%	33.74%	34.86%	34.72%	34.19%	34.05%	33.46%	33.9%	35.36%	35.73%	35.88%	36.45%	36.99%
Axis Mutual Fund Trustee Limited A/C Axis Mutual F___	1.77	1.65	—	—	—	—	—	—	—	—	—	—	—
Canara Robeco Mutual Fund A/C Canara Robeco Emergi___	1.04	1.04	—	—	—	—	—	—	—	—	—	—	—
Dsp Midcap Fund	5.39	5.51	6.65	6.73	6.9	7.13	6.43	5.97	6.12	6.19	6.5	6.52	—
Hdfc Life Insurance Company Limited	1.98	1.96	1.9	1.9	1.97	1.95	1.95	1.93	1.93	1.93	1.93	1.92	—
Hdfc Mutual Fund - Hdfc Mid-Cap Fund	—	—	—	—	—	—	—	—	—	—	—	9.5	—
Hdfc Mutual Fund - Hdfc Mid-Cap Opportunities Fund	—	—	6.64	7.22	7.27	7.03	8.7	9.14	8.46	8.47	9.05	—	—
Hdfc Trustee Company Ltd - A/C Hdfc Mid - Capoppor___	5.34	5.49	—	—	—	—	—	—	—	—	—	—	—
Hsbc Midcap Fund	1.04	—	—	—	—	—	—	—	—	—	—	—	—
Icici Prudential Balanced Advantage Fund	—	—	—	—	—	—	1.52	—	—	—	—	—	—
Icici Prudential Multi-Asset Fund	2.06	2.48	3.69	3.14	2.74	2.4	—	—	—	—	—	—	—
Kotak Emerging Equity Scheme	2.85	3.13	3.2	3.64	3.71	3.7	4.96	5.13	5.79	5.79	6.05	—	—
Kotak Midcap Fund	—	—	—	—	—	—	—	—	—	—	—	6.27	—
Mirae Asset Emerging Bluechip Fund	1.79	1.44	1.31	1.86	—	—	—	—	—	—	—	—	—
Nippon Life India Trustee Ltd- A/C Nippon India Gr___	2.41	2.24	2.07	1.47	1.62	1.7	1.89	1.91	2.02	2.25	2.18	2.21	—
Parag Parikh Flexi Cap Fund	1.24	1.26	1.46	1.46	1.46	1.46	1.46	1.46	1.46	—	—	—	—
Sbi Life Insurance Co_ Ltd	—	—	1.42	1.67	1.73	1.83	2.01	2.2	2.42	2.85	3.3	3.54	—
Uti Flexi Cap Fund	1.61	1.52	1.46	1.08	1.13	1.04	—	—	—	—	—	—	—
Government	0.32%	0.32%	0.32%	0.32%	0.32%	0.32%	0.32%	0.32%	0.32%	0.32%	0.32%	0.32%	0.32%
Public	9.22%	9.06%	8.46%	8.8%	8.93%	8.82%	9.07%	8.64%	8.53%	8.45%	8.41%	8.09%	7.33%
Others	—	—	—	—	—	—	—	—	—	—	—	—	—
No. of Shareholders	1,08,177	1,10,296	99,889	95,930	82,809	81,165	84,753	82,975	90,189	88,306	85,582	82,870	—

News & Updates

BSE Announcements

Direct from BSE filings, AI summarised

Ipca Laboratories to Sell Non-Operational US Subsidiary for USD 400,000 and Update Registered Office Address for Compliance

13 Jan 2026

Ipca Laboratories to Sell Inactive US Subsidiary Bayshore Pharma for USD 400,000; Updates Registered Office Details for DPIIT Compliance

13 Jan 2026

Ipca Laboratories Board Approves Sale of Non-Operational US Subsidiary for USD 4 Lakh and Registered Office Address Update

13 Jan 2026

Ipca Laboratories Files SEBI Compliance Certificate for Q4 FY26 Quarter

8 Jan 2026

Ipca Laboratories Announces Trading Window Closure Ahead of Q3 FY26 Results and Reports Strong Recent Performance

22 Dec 2025

Other Websites

External media mentions

Expert Trading Calls: Ipca Labs, MTAR, Equitas Lead Jan 12 Stock Ideas

12 Jan 2026

Indian Markets Dip: Over 180 Stocks Hit 52-Week Lows

8 Jan 2026

Jefferies Forecasts Weak Pharma H1 2026; Names Top Stock Picks

8 Jan 2026

Pharma Stocks Rally to 52-Week Highs, Outperforming Market

7 Jan 2026

Pharma Stocks Surge on Brokerage Optimism, CRDMO Growth Outlook

6 Jan 2026

News Articles

Editorial & research coverage

Jefferies Forecasts Weak Pharma H1 2026; Names Top Stock Picks

8 Jan 2026

Pharma Stocks Rally to 52-Week Highs, Outperforming Market

7 Jan 2026

Pharma Stocks Surge on Brokerage Optimism, CRDMO Growth Outlook

6 Jan 2026

India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?

15 Dec 2025

US FDA Inspects Ipca Labs API Plant: Key Observations Issued – What Investors Must Know NOW!

5 Dec 2025

Documents

Announcements

Sale Of 100% Equity Shares Of Wholly Owned Step-Down Subsidiary And Updation Of Registered Office Address

2d - Ipca to sell Bayshore LLC to Centaur for USD 400,000; agreement around Jan 20, 2026; completion within 30 days.

Announcement under Regulation 30 (LODR)-Change in Registered Office Address

2d - Ipca to sell Bayshore (US step-down subsidiary) to Centaur USA for USD 400,000; agreement around Jan 20, 2026.

Board Meeting Outcome for Outcome Of Board Meeting

2d - Ipca to sell Bayshore (US) to Centaur for USD 400,000; agreement around 20 Jan 2026; office district update.

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

8 Jan - Certificate under Regulation 74(5) confirming dematerialisation processing for quarter ended December 31, 2025.

Closure of Trading Window

null

Annual Reports

FY Financial Year 2025

(from bse)

FY Financial Year 2024

(from web)

FY Financial Year 2024

(from bse)

FY Financial Year 2023

(from web)

FY Financial Year 2023

(from bse)

FY Financial Year 2022

(from bse)

FY Financial Year 2021

(from bse)

FY Financial Year 2020

(from bse)

FY Financial Year 2019

(from bse)

FY Financial Year 2018

(from bse)

FY Financial Year 2017

(from bse)

FY Financial Year 2016

(from bse)

FY Financial Year 2015

(from bse)

FY Financial Year 2014

(from bse)

FY Financial Year 2013

(from bse)

Credit Ratings

Rating update

7 Jul 2025 from fitch

Rating update

15 Jul 2024 from fitch

Rating update

22 Sep 2023 from fitch

Rating update

27 Jul 2023 from fitch

Rating update

25 Jul 2023 from fitch

Rating update

18 Oct 2022 from care

Concalls

Nov 2025

Transcript Audio

Aug 2025

Transcript

Jun 2025

Transcript PPT

Feb 2025

Transcript PPT

Nov 2024

Transcript PPT

Aug 2024

Transcript

Jun 2024

Transcript

Feb 2024

Transcript

Nov 2023

Transcript

Aug 2023

Transcript

Apr 2023

Transcript

Feb 2023

Transcript

Nov 2022

Transcript

Aug 2022

Transcript

May 2022

Transcript

Feb 2022

Transcript

Nov 2021

Transcript

Aug 2021

Transcript

Jun 2021

Transcript

Jun 2021

Transcript

Mar 2021

Transcript

Nov 2020

Transcript

Aug 2020

Transcript

Jun 2020

Transcript

Feb 2020

Transcript

Nov 2019

Transcript

Aug 2019

Transcript

May 2019

Transcript

Feb 2019

Transcript

Nov 2018

Transcript

Ipca Laboratories Ltd

ABOUT

Stock Analysis

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

News & Updates

BSE Announcements

Other Websites

News Articles

Documents

Announcements

Annual Reports

Credit Ratings

Concalls